Cannabis for Combined Inflammatory and Neuropathic Pain

Preferred Starting Profile

Balanced CBD:THC, approximately 1:1, with a β caryophyllene rich terpene profile, has the best available support as a starting point.

Human evidence remains low to very low certainty, particularly for specific terpene combinations. Cannabis products are generally considered later line therapy after standard neuropathic pain medications have failed or are not tolerated.

CBD:THC Ratio

Ratio

Evidence / Considerations

Balanced, ~1:1

Best human evidence. May provide modest improvement in neuropathic pain with better tolerability than THC dominant products.

THC dominant

May modestly reduce pain, but increases dizziness, sedation, nausea, and cognitive effects.

CBD dominant

Lower psychoactive risk, but substantially weaker evidence for analgesia.

CBD alone

Generally well tolerated, but has not demonstrated consistent benefit for chronic neuropathic pain.

Practical approach: Start with a balanced or CBD leaning product, use the lowest THC dose, and titrate slowly according to benefit and adverse effects.

Terpenes of Greatest Interest

β Caryophyllene: Strongest preclinical candidate for combined inflammatory and neuropathic pain. Acts primarily through CB2 receptors.

α Humulene: Anti inflammatory and analgesic activity, possibly involving TRPV1 modulation.

α Terpineol: Demonstrated reduction of mechanical allodynia and thermal hyperalgesia in animal models.

Linalool: Preclinical antinociceptive and neuropathic pain activity.

Limonene: Anti inflammatory and antinociceptive activity through several proposed pathways.

α Bisabolol: Potential neuropathic and inflammatory analgesia through calcium channel modulation.

Suggested Profile

Consider:

CBD:THC approximately 1:1

with emphasis on:

β caryophyllene + α humulene + linalool or α terpineol

Optional secondary terpenes include limonene or α bisabolol.

Key Limitation

Terpene specific pain benefits and the proposed cannabis “entourage effect” remain largely preclinical and are not established by high quality human trials. THC related adverse effects remain dose dependent.